

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

10X GENOMICS, INC.,)	
)	
Plaintiff,)	
)	
v.)	C.A. No. _____
)	
PARSE BIOSCIENCES, INC.,)	DEMAND FOR JURY TRIAL
)	
Defendant,)	
)	
and)	
)	
THE BOARD OF TRUSTEES OF LELAND)	
STANFORD JUNIOR UNIVERSITY)	
)	
Nominal Defendant.)	

**COMPLAINT FOR PATENT INFRINGEMENT AND
DECLARATORY JUDGMENT FOR PATENT INFRINGEMENT**

Plaintiff 10x Genomics, Inc. (“10x” or “Plaintiff”) for its Complaint against Defendant Parse Biosciences, Inc. (“Parse”), alleges as follows:

NATURE OF THE ACTION

1. This is an action for infringement of United States Patent Nos. 10,155,981 (“the ’981 Patent”), 10,697,013 (“the ’013 Patent”), 10,240,197 (“the ’197 Patent”), 10,150,995 (“the ’995 Patent”), 10,619,207 (“the ’207 Patent”), and 10,738,357 (“the ’357 Patent”) (collectively, the “Asserted Patents”). This action arises under the patent laws of the United States, Title 35, United States Code, including 35 U.S.C. §271, and the Declaratory Judgment Act, Title 28, United States Code, including §§ 2201, 2202.

THE PARTIES

2. 10x is a Delaware corporation with its principal place of business at 6230 Stoneridge Mall Road, Pleasanton, California 94588.

3. 10x is a pioneering innovator of genomics and sequencing technologies that are providing life science researchers an unprecedented understanding of biology. By elegantly combining its proprietary hardware, chemistry, and software, 10x has developed and brought to market award-winning products that give single-cell and spatial views of complex biological systems. 10x's products have enabled previously infeasible forms of research in the life sciences in areas of critical importance to human health, including cancer research, neuroscience, immunology, infectious disease, and developmental biology. 10x is the owner of the '981, '013, and '197 Patents, and the exclusive licensee of the '995, '207, and '357 Patents pursuant to an exclusive license agreement with the Board of Trustees of Leland Stanford Junior University ("Stanford University"). 10x is pursuing this action and has the right to join Stanford University, the owner and licensor of the '995, '207, and '357 Patents, as a party in accordance with the terms of its exclusive license agreement with Stanford University.

4. Stanford University is a trust possessing corporate powers that is organized under the laws of the State of California and with its principal place of business at the Office of the President, Building 10 Main Quad, Stanford, California 94305. Stanford University is owner and licensor of the '995, '207, and '357 Patents. Stanford University is named as a nominal defendant in this action for purposes of subject matter jurisdiction only and pursuant to the United States Supreme Court's holding in *Independent Wireless Telegraph Co. v. Radio Corp. of America*, 269 U.S. 459, 468 (1926), that "[i]f the owner of a patent, being within the jurisdiction, refuses or is unable to join an exclusive licensee as coplaintiff, the licensee may make him a party defendant by process, and he will be lined up by the court in the party character which he should assume."

10x requested that Stanford University join as a party in this action, but Stanford University has thus far not agreed to do so. Although Stanford University is named as a nominal defendant, 10x seeks relief realigning Stanford University as a plaintiff.

5. On information and belief, Parse is a Delaware corporation with its principal place of business at 201 Elliott Avenue W, Suite 290, Seattle, Washington 98119.

6. Parse is infringing and will infringe the patents asserted in this action by its manufacture, use, sale, offer to sell, sale, and/or importation into the United States of products, services, and components that are and/or will be used by Parse and its customers to infringe at least Claim 1 of each of the '981, '013, '197, '995, and '207 Patents and Claim 16 of the '357 Patent.

JURISDICTION AND VENUE

7. 10x incorporates and realleges paragraphs 1 to 6 above as if fully set forth herein.

8. This civil action for patent infringement arises under the patent laws of the United States, 35 U.S.C § 1 et seq., including in particular under 35 U.S.C. § 271. This Court has subject matter jurisdiction pursuant to 28 U.S.C. §§ 1331, 1338(a).

9. This Court has personal jurisdiction over Parse, and venue is proper in this district pursuant to 28 U.S.C. § 1400(b), because Parse is a Delaware corporation and thus resides in this district.

10. This Court has personal jurisdiction over nominal defendant Stanford University because Stanford University has substantial contacts with the forum as a consequence of conducting business and activities in Delaware, including having filed lawsuits in this forum.

BACKGROUND

11. 10x incorporates and realleges paragraphs 1 to 10 above as if fully set forth herein.

A. 10x's Groundbreaking Single-Cell Technologies

12. 10x is a life sciences technology company founded in 2012 in Pleasanton, California by Drs. Serge Saxonov and Benjamin Hindson. Since its inception, 10x has focused on building new technologies to enable breakthrough discoveries and accelerate the understanding of biology. To date, 10x has invested hundreds of thousands of hours and over \$1 billion in research and development to invent, design, and develop its proprietary line of products for understanding biology at unprecedented resolution and scale. 10x continues to invest significant time and money to further innovate and bring groundbreaking new products and capabilities to market.

13. 10x is a worldwide leader in genomics, the comprehensive study of biological systems at a molecular and cellular level. 10x provides end-to-end solutions for genomic analysis, including instruments, reagent kits, and analysis software that enable researchers to obtain and interpret vast quantities of complex biological data. Since 10x's first commercial launch in 2015, 10x's expanding suite of products has fueled a revolution in genomics, winning wide acclaim and commercial success. 10x has sold more than 3,500 instruments around the world, including at all of the top 100 global research institutions and all of the top 20 global biopharmaceutical companies. In 2021, annual sales of 10x products exceeded \$490 million.

14. Over 3,800 scientific articles have been published based on data generated from 10x products, including hundreds of articles in top journals such as *Cell*, *Science*, and *Nature*. This scientific work details the use of 10x products to discover, for example: molecular mechanisms that lead to brain, breast, and lung cancers; how the immune system reacts to COVID-19 infection; and a new type of lung cell that causes cystic fibrosis. The paradigm-changing nature of 10x's

products has led to numerous accolades, including seven 10x products being named to *The Scientist* magazine's Top 10 Innovations list between 2015 and 2021.

15. 10x's Chromium platform has been essential to enabling single-cell genomics—the study of biology at a cell-by-cell resolution and at a massive, system-wide scale, ushering in a single-cell revolution hailed by *Science* magazine as the 2018 “Breakthrough of the Year.” Whereas traditional biology relies on “bulk analysis” in which tissue is analyzed as averages across the sample, 10x's breakthrough single-cell products enable researchers to analyze samples on a single cell basis—for millions of cells per experiment—thereby preserving information that is specific to each cell in the sample. 10x's single-cell products do this by “tagging” the molecules of each single cell with a unique nucleic acid barcode, which can then be analyzed to trace the molecule's cellular origin. The Chromium X instrument, which launched in July 2021 and facilitates cost-effective million-cell experiments, is the latest addition to 10x's award-winning platform and was named a Top 10 Innovation in 2021 by *The Scientist* magazine, <https://www.the-scientist.com/features/2021-top-10-innovations-69438>.

16. A key strength of 10x's Chromium platform lies in its suite of products that use 10x's proprietary molecular assays to probe the various essential constituents of biology—e.g., DNA, RNA, protein, and epigenetics—within a given sample. 10x launched its flagship single-cell product, Chromium Single Cell Gene Expression, in 2016. In addition to providing researchers with the ability to measure gene activity from RNA on a cell-by-cell basis, Single Cell Gene Expression is a versatile product that utilizes 10x's Feature Barcoding technology to enable single-cell protein analysis and single-cell CRISPR screening. 10x's Chromium Single Cell Immune Profiling product, launched in 2017, enables researchers to unravel the vast complexity of adaptive immunity by examining T-cells and B-cells at single cell resolution. 10x's Chromium

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.